It is with mixed emotions that I share the news that John Young, Pfizer’s Chief Business Officer, will retire in early 2022, following a distinguished 34-year career at Pfizer. John’s list of significant accomplishments at Pfizer is long, but perhaps none is more important than his essential role in cultivating the collaborations that led to the successful development and delivery of the Pfizer-BioNTech COVID-19 vaccine.
During his time at Pfizer, John has led many large-scale transformations, including the closing of the joint venture with GlaxoSmithKline to create a premier global consumer healthcare business in 2019. John also has steered many strategic processes to maximize our portfolio and robust pipeline, and he has represented our company with great distinction in leadership positions on several prominent global organizations, including service as a member of the board of BIO.
John is a well-respected leader whose dedication and passion for helping patients and advancing our purpose have had a huge impact on our success. Admired for his keen intellect and analytical rigor, along with his strong personal values and integrity, he has been a trusted advisor and remains a valued friend.
John will continue in his role while we conduct a search for his replacement and has agreed to continue in an advisory role for a period of time in 2022. All of us at Pfizer wish John and his family good health and happiness in the next chapter of their lives.